香港股市 將在 4 小時 38 分鐘 開市

Recursion Pharmaceuticals, Inc. (RXRX)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
9.37+0.11 (+1.19%)
收市:04:00PM EDT
9.32 -0.05 (-0.53%)
收市後: 04:48PM EDT

Recursion Pharmaceuticals, Inc.

41 South Rio Grande Street
Salt Lake City, UT 84101
United States
385 269 0203
https://www.recursion.com

版塊Healthcare
行業Biotechnology
全職員工500

高階主管

名稱頭銜支付行使價出生年份
Dr. Christopher C. Gibson Ph.D.Co-Founder, CEO & Director806.72k2.18M1983
Ms. Tina Marriott LarsonCOO & President702.24k397.61k1975
Dr. Blake C. Borgeson Ph.D.Co-Founder & Director40k1982
Dr. Michael Secora Ph.D.Chief Financial Officer629.78k3.62M1983
Dr. David J. Mauro M.D., Ph.D.Chief Medical Officer674.74k1965
Kevin LeggatVice President of Finance & Accounting
Mr. Benjamin Mabey M.S.Chief Technology Officer1983
Mr. Jared AllenbachSenior Director of Investor Relations
Mr. Nathan HatfieldChief Legal Officer & General Counsel
Mr. Ryan KellyChief Communications Officer
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

公司管治

截至 2024年6月1日 止,Recursion Pharmaceuticals, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中:3;董事會:6;股東權利:10;現金賠償:9。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。